Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682499 · ClinicalTrials.gov registry record · Phase 1
Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy
A Phase 1 study, sponsored by Beth Israel Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01682499 is a Phase 1 study that has completed, run by Beth Israel Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT01682499, a Phase 1 study, has completed, sponsored by Beth Israel Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a pilot study evaluating the feasibility of intravenous calcium and magnesium (Ca/Mg) infusion for prevention of taxane induced neuropathy in patients with early stage breast cancer receiving adjuvant or neo-adjuvant paclitaxel, either given every 2 weeks for 4 cycles or every week for 12 weeks.
Interventions
- DRUG calcium gluconate and magnesium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682499
The ClinicalTrials.gov registry entry for NCT01682499 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which calcium gluconate and magnesium sulfate is the first listed.
NCT01682499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682499 about?
NCT01682499 is a clinical study titled "Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy". This is a pilot study evaluating the feasibility of intravenous calcium and magnesium (Ca/Mg) infusion for prevention of taxane induced neuropathy in patients with early stage breast cancer receiving adjuvant or neo-adjuvant paclitaxel, either given every 2 weeks for 4 cycles or every week for 12 we...
What is the current status of trial NCT01682499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01682499?
The interventions under investigation include: calcium gluconate and magnesium sulfate (DRUG).
Who is sponsoring clinical trial NCT01682499?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.